A landmark multicenter trial published in The New England Journal of Medicine has challenged conventional surgical practice for Chiari I malformation, finding that adding duraplasty to decompression surgery provides minimal additional benefit for patients with syringomyelia.
Chiari I Surgery Success Rates by Procedure Type
Percentage of patients achieving primary endpoint at 24 months
Source: NEJM, 2026 | Georgian Medical Journal News
Largest Chiari Trial Challenges Standard Practice
The randomized controlled trial enrolled patients across multiple medical centers, comparing posterior fossa decompression with and without duraplasty in patients diagnosed with Chiari I malformation and syringomyelia, according to the study published in The New England Journal of Medicine.
The study followed patients for 24 months, measuring success based on a composite endpoint that included symptom improvement and radiological changes. The research showed both surgical approaches had substantial success rates, but the difference between them was smaller than anticipated.
Dr. John Heiss, senior investigator at the National Institute of Neurological Disorders and Stroke and lead author of the study, was quoted in the NEJM publication regarding the study’s implications for surgical decision-making in Chiari I patients.
Surgical Complications Show Similar Profiles
Both surgical approaches demonstrated comparable safety profiles, with serious complications occurring in fewer than 5% of patients in each group, according to the NEJM study. The most common adverse events included cerebrospinal fluid leaks, wound infections, and temporary neurological symptoms.
The duraplasty group showed a slightly higher rate of cerebrospinal fluid-related complications, as documented in the study’s safety analysis published in The New England Journal of Medicine. The overall complication rates were within expected ranges for both procedures, and most adverse events resolved with appropriate medical management according to the study data.
For patients considering surgery, this data from the NEJM trial provides evidence about both approaches while highlighting the importance of experienced surgical teams. The clinical implications extend beyond individual patient care to surgical training and healthcare resource allocation.
Syringomyelia Response Varies by Patient Characteristics
The NEJM study revealed insights about which patients are most likely to benefit from each surgical approach. According to the subgroup analyses published in the trial, patients with larger syrinxes showed greater improvement with duraplasty, while those with smaller cavities responded similarly to both procedures.
Age at surgery also influenced outcomes according to the study, with younger patients demonstrating better response rates regardless of surgical technique. The research team found that preoperative symptom severity was a strong predictor of postoperative improvement based on their trial data.
These findings from the NEJM study suggest that personalized surgical decision-making based on patient characteristics may optimize outcomes. The study provides a framework for surgeons to discuss treatment options with patients, moving toward evidence-based surgical planning.
Healthcare Economics and Future Research Directions
The minimal difference in effectiveness between the two procedures demonstrated in the NEJM trial has implications for healthcare costs and surgical training programs. Duraplasty requires additional operative time and specialized techniques, factors that influence both direct costs and surgeon training requirements.
The study team identified future research priorities including longer-term follow-up studies and investigation of biomarkers that might predict which patients would benefit most from duraplasty, as noted in their NEJM publication.
The trial’s methodology provides a template for future neurosurgical research, demonstrating how complex surgical questions can be addressed through rigorous randomized controlled trials according to the published study.
After 24 months, 65.3% of patients who underwent decompression with duraplasty achieved the primary endpoint compared to 63.1% of those who had decompression alone, a difference that was not statistically significant.
— Study results from The New England Journal of Medicine, 2026
Key takeaways from the NEJM study
- Both surgical approaches showed high success rates above 60% at 24 months
- Duraplasty provided minimal additional benefit over decompression alone
- Patient characteristics like syrinx size and age influence surgical outcomes
- Complication rates were low and similar between both surgical approaches
Frequently asked questions
What is Chiari I malformation and why does it require surgery?
Chiari I malformation occurs when brain tissue extends into the spinal canal, often causing syringomyelia (fluid-filled cavities in the spinal cord). Surgery is recommended when patients experience symptoms like headaches, neck pain, or neurological deficits that significantly impact quality of life.
How should patients choose between decompression with or without duraplasty?
Based on this NEJM study, the decision should be individualized based on factors like syrinx size, patient age, and symptom severity. The study suggests both approaches are effective, so patients should discuss with experienced neurosurgeons about which option best fits their specific clinical picture.
What does this study mean for current Chiari surgery practices?
The NEJM findings support either surgical approach as reasonable options, potentially leading to more personalized decision-making rather than defaulting to one technique. Surgeons may increasingly consider patient-specific factors when recommending surgical strategies.
This landmark NEJM trial provides the highest level of evidence to date for Chiari I surgical decision-making, offering patients and surgeons clearer guidance about treatment options. The findings will likely influence neurosurgical training programs and clinical practice guidelines, while opening new avenues for research into personalized surgical approaches for complex neurological conditions.
Source: Decompression with or without Duraplasty for Chiari I and Syringomyelia
